



**OSE Immunotherapeutics will present at the
Rodman & Renshaw 18th Annual Global Investment Conference
in New York City, September 11-13, 2016**

Nantes, Paris, August 30, 2016 - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotechnology company developing immunotherapies of activation or regulation in immuno-oncology, auto-immune diseases and transplantation, today announced it will be featured as a presenting company at the Rodman & Renshaw 18th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City.

Dominique Costantini, Chief Executive Officer of OSE Immunotherapeutics, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

"With first-in-class immuno-oncology and immunotherapy products ranging from R&D to Phase III registration studies and a first global pharmaceutical agreement with Janssen Biotech (Johnson & Johnson group) on FR104 (CD-28 antagonist), we are in a good position to reinforce our visibility in the U.S.. Our strong position in these very attractive markets is a major asset and we look forward to updating investors with our progress and prospects," said Dominique Costantini.

Date: September 12, 2016

Day and Time: 11:40-12:05 PM (Eastern Time)

Location: Kennedy I Room, 4th Floor; Lotte New York Palace Hotel in New York City

The presentation will be webcast live. To access the webcast, please visit: www.rodmanevents.com or the company's website: <http://ose-immuno.com/en/>. The webcast replay will remain available for 90 days following the live presentation.

If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

ABOUT OSE IMMUNOTHERAPEUTICS

OSE Immunotherapeutics is a biotechnology company specializing in immune regulation with clinical applications in immuno-oncology, autoimmune diseases and transplantation. The company has a balanced portfolio, from R&D to clinical phase 3 registration, with a diversified risk profile. It is composed of advanced immunotherapy products in clinical pivotal phase 3 and in phase 2 with Tedopi® (combined neoepitopes in oncology, developed in advanced lung cancer, NSCLC); and FR104 with phase 1 completed (a CD28-antagonist Immunotherapy licensed to Janssen Biotech Inc.). The company also has promising products in preclinical phase and potential drug candidates in R&D, targeting new receptors of interest in immuno-oncology, autoimmune diseases, and transplantation. This product portfolio is supported by an innovative technology foundation and know-how in

selection and optimization of new generation products acting on new immunological targets, notably Effi-DEM, a new generation check-point inhibitor targeting the SIRP- α receptor on strategic CD47/SIRP- α pathway (blockage of suppressive myeloid and macrophage cells) and Effi-7, an immunomodulator, interleukin-7 antagonist, developed for autoimmune diseases and transplantation.

Contacts

OSE Immunotherapeutics

Dominique Costantini, CEO
dominique.costantini@ose-immuno.com

Mob +33 6 13 20 77 49

Maryvonne Hiance, Vice-Présidente
maryvonne.hiance@ose-immuno.com

Tél : +33 (0) 240 412 834

Mobile : 33 (0) 680 060 183

Alexis Peyroles, DGD, Operations,
 Finance & BD
alexis.peyroles@ose-immuno.com

Mob : +33 6 11 51 19 77

Bernard Vanhove, DGD, R&D,
 Collaborations scientifiques
Bernard.vanhove@ose-immuno.com

Mob: +33 6 75 41 40 08

Contacts media

Citigate Dewe Rogerson

Laurence Bault
laurence.bault@citigate.fr

+33 1 53 32 84 78

Alize RP

Florence Portejoie & Caroline Carmagnol

oseimmuno@alizerp.com

+33 6 47 38 90 04

Consilium Strategic Communications

Chris Gardner / Matthew Neal /

Hendrik Thys

OSEImmuno@consilium-comms.com

+44 (0) 20 3709 5700

Rx Communications Group, LLC

Melody Carey

mcarey@rxir.com

+ 1 917-322-2571

Forward-looking statements

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import.

Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance.

This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 8 June 2016 under the number R.15-052, the consolidated financial statements and the management report for the fiscal year 2015, as well as the Merger Document registered with the AMF on 26 April 2016 under number E.16-026, all available on the OSE Immunotherapeutics' website.

Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.